Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5666368 | 0.94 | KMT2A (0.51) | ADRA1DADRA1AADRA1BDRD2FAAH | |
| SCHEMBL5655895 | 0.91 | MEN1 (0.57) | ADRA1DADRA1AADRA1BDRD2DRD3 | |
| SCHEMBL5655907 | 0.90 | ADRA1D (0.53) | ADRA1DADRA1AADRA1BDRD2HTR2A | |
| SCHEMBL5654887 | 0.90 | ADRA1A (0.66) | ADRA1DADRA1AADRA1BDRD2DRD3 | |
| SCHEMBL5655927 | 0.90 | ADRA1A (0.62) | ADRA1DADRA1AADRA1BDRD2HTR2A | |
| SCHEMBL5656119 | 0.89 | PKM (0.61) | ADRA1DADRA1AADRA1BLMNAMAPT | |
| SCHEMBL5655836 | 0.86 | GAA (0.50) | LMNAMAPTKMT2A | |
| SCHEMBL5657183 | 0.85 | DRD2 (0.55) | ADRA1DADRA1AADRA1BDRD2DRD3 | |
| SCHEMBL5656021 | 0.84 | MAPT (0.58) | ADRA1ADRD2DRD3HTR2AHTR7 | |
| SCHEMBL5656051 | 0.84 | MAPT (0.56) | DRD2DRD3HTR2AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
| EP-1362041-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | Cerep (FR) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002068399-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | CEREP (FR) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | ADRA1D 265/4885ADRA1A 294/4885ADRA1B 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.